COMBINED ANTIHYPERTENSIVE THERAPY: FOCUS ON A FIXED-DOSE COMBINATION OF AN ACE INHIBITOR AND A DIURETIC
The study aimed to assess the effectiveness and safety of a fixed-dose combination of an ACE inhibitor (losartan) and a diuretic (hydrochlorothiazide) in patients with arterial hypertension (AH) and high or very high cardiovascular risk. The study included 30 patients with Stage I-III AH (13 men and...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2010-10-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1497 |
| _version_ | 1826561522872090624 |
|---|---|
| author | Z. T. Astakhova F. U. Kanukova A. V. Rappoport I. Zh. Tautieva Zh. A. Kulova Z. Z. Dzukaeva V. A. Aydarova |
| author_facet | Z. T. Astakhova F. U. Kanukova A. V. Rappoport I. Zh. Tautieva Zh. A. Kulova Z. Z. Dzukaeva V. A. Aydarova |
| author_sort | Z. T. Astakhova |
| collection | DOAJ |
| description | The study aimed to assess the effectiveness and safety of a fixed-dose combination of an ACE inhibitor (losartan) and a diuretic (hydrochlorothiazide) in patients with arterial hypertension (AH) and high or very high cardiovascular risk. The study included 30 patients with Stage I-III AH (13 men and 17 women; mean age 51,9±1,9 years). For 12 weeks, the participants were administered a combination of losartan (50 mg) and hydrochlorothiazide (12,5 mg; once a day, in the morning). Echocardiography and 24-hour blood pressure monitoring (BPM) were performed. In 2 and 4 weeks, a reduction in office systolic BP (SBP) and office diastolic BP (DBP), respectively, was observed. In 12 weeks, BP reduction was even more pronounced, with a reduction in 24-hour SBP (from 141,9±1,9 to 128,6±0,8 mm Hg; p<0,001), daytime SBP (from 146,8±2,6 to 135,8±1,0 mm Hg; p><0,01), and nighttime SBP (from 131,5±1,9 to 118,8±1,9 mm Hg; p><0,001). A reduction was also observed for 24-hour DBP (from 91,7±1,8 to 78,7±1,6 mm Hg; p><0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p><0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,001), daytime SBP (from 146,8±2,6 to 135,8±1,0 mm Hg; p<0,01), and nighttime SBP (from 131,5±1,9 to 118,8±1,9 mm Hg; p><0,001). A reduction was also observed for 24-hour DBP (from 91,7±1,8 to 78,7±1,6 mm Hg; p><0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p><0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,01), and nighttime SBP (from 131,5±1,9 to 118,8±1,9 mm Hg; p<0,001). A reduction was also observed for 24-hour DBP (from 91,7±1,8 to 78,7±1,6 mm Hg; p><0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p><0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,001). A reduction was also observed for 24-hour DBP (from 91,7±1,8 to 78,7±1,6 mm Hg; p<0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p><0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p<0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p<0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p<0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p<0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p<0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness. |
| first_indexed | 2024-04-09T20:52:39Z |
| format | Article |
| id | doaj.art-e8c539c5449f440185dea58491de8b80 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2025-03-14T09:33:31Z |
| publishDate | 2010-10-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-e8c539c5449f440185dea58491de8b802025-03-02T11:42:27Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202010-10-010568721284COMBINED ANTIHYPERTENSIVE THERAPY: FOCUS ON A FIXED-DOSE COMBINATION OF AN ACE INHIBITOR AND A DIURETICZ. T. Astakhova0F. U. Kanukova1A. V. Rappoport2I. Zh. Tautieva3Zh. A. Kulova4Z. Z. Dzukaeva5V. A. Aydarova6ГОУ ВПО Северо-Осетинская государственная медицинская академия Росздрава, кафедра госпитальной терапии с ЛФК и ВК, ВладикавказГОУ ВПО Северо-Осетинская государственная медицинская академия Росздрава, кафедра госпитальной терапии с ЛФК и ВК, ВладикавказГОУ ВПО Северо-Осетинская государственная медицинская академия Росздрава, кафедра госпитальной терапии с ЛФК и ВК, ВладикавказГОУ ВПО Северо-Осетинская государственная медицинская академия Росздрава, кафедра госпитальной терапии с ЛФК и ВК, ВладикавказГОУ ВПО Северо-Осетинская государственная медицинская академия Росздрава, кафедра госпитальной терапии с ЛФК и ВК, ВладикавказГОУ ВПО Северо-Осетинская государственная медицинская академия Росздрава, кафедра госпитальной терапии с ЛФК и ВК, ВладикавказГОУ ВПО Северо-Осетинская государственная медицинская академия Росздрава, кафедра госпитальной терапии с ЛФК и ВК, ВладикавказThe study aimed to assess the effectiveness and safety of a fixed-dose combination of an ACE inhibitor (losartan) and a diuretic (hydrochlorothiazide) in patients with arterial hypertension (AH) and high or very high cardiovascular risk. The study included 30 patients with Stage I-III AH (13 men and 17 women; mean age 51,9±1,9 years). For 12 weeks, the participants were administered a combination of losartan (50 mg) and hydrochlorothiazide (12,5 mg; once a day, in the morning). Echocardiography and 24-hour blood pressure monitoring (BPM) were performed. In 2 and 4 weeks, a reduction in office systolic BP (SBP) and office diastolic BP (DBP), respectively, was observed. In 12 weeks, BP reduction was even more pronounced, with a reduction in 24-hour SBP (from 141,9±1,9 to 128,6±0,8 mm Hg; p<0,001), daytime SBP (from 146,8±2,6 to 135,8±1,0 mm Hg; p><0,01), and nighttime SBP (from 131,5±1,9 to 118,8±1,9 mm Hg; p><0,001). A reduction was also observed for 24-hour DBP (from 91,7±1,8 to 78,7±1,6 mm Hg; p><0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p><0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,001), daytime SBP (from 146,8±2,6 to 135,8±1,0 mm Hg; p<0,01), and nighttime SBP (from 131,5±1,9 to 118,8±1,9 mm Hg; p><0,001). A reduction was also observed for 24-hour DBP (from 91,7±1,8 to 78,7±1,6 mm Hg; p><0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p><0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,01), and nighttime SBP (from 131,5±1,9 to 118,8±1,9 mm Hg; p<0,001). A reduction was also observed for 24-hour DBP (from 91,7±1,8 to 78,7±1,6 mm Hg; p><0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p><0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,001). A reduction was also observed for 24-hour DBP (from 91,7±1,8 to 78,7±1,6 mm Hg; p<0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p><0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,05), daytime DBP (from 94,3±1,3 to 85,0±1,2 mm Hg; p<0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p><0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,05), and nighttime DBP (from 83,5±2,0 to 71,2±1,7 mm Hg; p<0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p><0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,01). Circadian BP variability, time BP index, and morning BP surge were also decreased (from 37,6±2,0 to 23,9±1,9 mm Hg; p<0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p><0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,001). After 12 weeks of the combined therapy with losartan and hydrochlorothiazide, circadian BP profile was normalized in most participants. There was a reduction in the percentage of the patients with myocardial hypertrophy (from 50% to 30%; p<0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p><0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,01) or left ventricular diastolic dysfunction (from 43,3% to 30%; p<0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.>< 0,05). Therefore, a fixed-dose combination of losartan and hydrochlorothiazide (50 mg + 12,5 mg) demonstrated good antihypertensive and cardioprotective effectiveness.https://russjcardiol.elpub.ru/jour/article/view/1497arterial hypertensionmyocardial hypertrophylosartanhydrochlorothiazide |
| spellingShingle | Z. T. Astakhova F. U. Kanukova A. V. Rappoport I. Zh. Tautieva Zh. A. Kulova Z. Z. Dzukaeva V. A. Aydarova COMBINED ANTIHYPERTENSIVE THERAPY: FOCUS ON A FIXED-DOSE COMBINATION OF AN ACE INHIBITOR AND A DIURETIC Российский кардиологический журнал arterial hypertension myocardial hypertrophy losartan hydrochlorothiazide |
| title | COMBINED ANTIHYPERTENSIVE THERAPY: FOCUS ON A FIXED-DOSE COMBINATION OF AN ACE INHIBITOR AND A DIURETIC |
| title_full | COMBINED ANTIHYPERTENSIVE THERAPY: FOCUS ON A FIXED-DOSE COMBINATION OF AN ACE INHIBITOR AND A DIURETIC |
| title_fullStr | COMBINED ANTIHYPERTENSIVE THERAPY: FOCUS ON A FIXED-DOSE COMBINATION OF AN ACE INHIBITOR AND A DIURETIC |
| title_full_unstemmed | COMBINED ANTIHYPERTENSIVE THERAPY: FOCUS ON A FIXED-DOSE COMBINATION OF AN ACE INHIBITOR AND A DIURETIC |
| title_short | COMBINED ANTIHYPERTENSIVE THERAPY: FOCUS ON A FIXED-DOSE COMBINATION OF AN ACE INHIBITOR AND A DIURETIC |
| title_sort | combined antihypertensive therapy focus on a fixed dose combination of an ace inhibitor and a diuretic |
| topic | arterial hypertension myocardial hypertrophy losartan hydrochlorothiazide |
| url | https://russjcardiol.elpub.ru/jour/article/view/1497 |
| work_keys_str_mv | AT ztastakhova combinedantihypertensivetherapyfocusonafixeddosecombinationofanaceinhibitorandadiuretic AT fukanukova combinedantihypertensivetherapyfocusonafixeddosecombinationofanaceinhibitorandadiuretic AT avrappoport combinedantihypertensivetherapyfocusonafixeddosecombinationofanaceinhibitorandadiuretic AT izhtautieva combinedantihypertensivetherapyfocusonafixeddosecombinationofanaceinhibitorandadiuretic AT zhakulova combinedantihypertensivetherapyfocusonafixeddosecombinationofanaceinhibitorandadiuretic AT zzdzukaeva combinedantihypertensivetherapyfocusonafixeddosecombinationofanaceinhibitorandadiuretic AT vaaydarova combinedantihypertensivetherapyfocusonafixeddosecombinationofanaceinhibitorandadiuretic |